Physician profile
Danny Douglas
NPI 1023165321
$2,369.11
in general payments reported to CMS, 2019-2025
18 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $238 · 2021: $483 · 2022: $402 · 2023: $336 · 2024: $379 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.26 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,089.70 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $528.18 | 2019-2025 | Arexvy, Nucala |
| Teva Pharmaceuticals USA, INC. | $130.38 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $109.64 | 2021-2023 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $80.48 | 2025 | |
| Optinose US, INC. | $69.50 | 2021-2023 | |
| Genzyme Corporation | $56.34 | 2019-2023 | |
| Pfizer INC. | $51.41 | 2021-2023 | |
| Amgen INC. | $45.11 | 2022 | |
| Csl Behring | $33.05 | 2025 | Hizentra |
| Abbvie INC. | $31.68 | 2021-2024 | |
| Mylan Specialty L.P. | $31.08 | 2020-2021 | |
| Kaleo, INC. | $25.13 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.73 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.07 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $16.81 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.76 | 2021 | |
| Pharming Healthcare, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.